The cord blood banking market is complex. There are regions experiencing growth and regions experiencing decline. There are extremely successful cord blood banks, and banks that are going out of business or being acquired by the competition.
In addition, there are unique opportunities occurring within the cord blood space that are based on emerging technologies, such as ex vivo expansion of cord blood.
The cord tissue market is also complex, although for different reasons. Today, half of all cord blood banks worldwide offer this service and the number is accelerating. Interestingly, the mesenchymal stem cells (MSCs) contained in cord tissue may have growing opportunities relative to the hematopoietic stem cells (HSCs) contained in cord blood, because MSCs just surpassed HSCs in the scientific literature for the first time in history.
For this reason, BioInformant is offering industry-leading market intelligence for both cord blood and cord tissue markets for the next 14 days only.
Act by Feb 29, 2016, and you can get two reports for the price of one, a savings of $3,795.
CORD BLOOD + CORD TISSUE PACKAGE:
- Complete 2015-16 Global Cord Blood Banking Industry Report
- Mesenchymal Stem Cells – Advances & Applications
This is an exclusive offer available only to BioInformant readers, so enter the coupon code “CordBloodCordTissue” during checkout (for either product) and you will automatically receive the other report for free.
To compete within the global cord blood banking market, you need to be informed about both cord blood and cord tissue markets. This is your opportunity to get a strategic edge.
Want to be better informed than your competition? Get future stem cell industry updates.
BioInformant is the only research firm that has served the stem cell sector since it emerged. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson, BioInformant is your global leader in stem cell industry data.